Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7120572 | 0.89 | EPHX2 (0.49) | EPHX2NPC1RAB9ASCN9APOLB | |
| SCHEMBL7122473 | 0.86 | EPHX2 (0.39) | EPHX2NPC1RAB9ASCN9AEGLN1 | |
| SCHEMBL7125155 | 0.85 | POLB (0.41) | NPC1RAB9ASCN9AFPR2EGLN1 | |
| SCHEMBL7122583 | 0.85 | POLB (0.50) | NPC1RAB9ASCN9AEGLN1POLB | |
| SCHEMBL7119283 | 0.85 | POLB (0.46) | SCN9APRKAA2POLBSMN1; SMN2 | |
| SCHEMBL7123339 | 0.85 | POLB (0.43) | SCN9APOLBSMN1; SMN2 | |
| SCHEMBL7117106 | 0.83 | SCN9A (0.56) | SCN9A | |
| SCHEMBL7123432 | 0.83 | MMP2 (0.39) | EPHX2NPC1RAB9ASCN9AEGLN1 | |
| SCHEMBL7125203 | 0.83 | EPHX2 (0.40) | EPHX2NPC1RAB9ASCN9AP2RX3 | |
| SCHEMBL7126711 | 0.82 | HRH3 (0.47) | NPC1RAB9ASCN9APRKAA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | EPHX2 194/4885NPC1 267/4885RAB9A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.